Role of matrix metalloproteinases in inflammatory bowel disease.

Recent evidence demonstrates that the increased expression and activity of matrix metalloproteinases (MMPs) may contribute to intestinal tissue injury and inflammation in inflammatory bowel disease, and that MMP inhibition might be a new therapeutic approach to controlling inflammatory response. In addition, MMPs may play a crucial role in physiological and pathophysiological reactions such as leukocyte accumulation into inflamed tissue, cytokine production from inflammatory and epithelial cells, T lymphocyte homing to the intestine, wound healing and proliferation of epithelial cells, and intestinal innate immunity. This review focuses on recent progress in elucidating the biological and pathological roles of MMPs in inflammatory bowel disease.

[1]  M. Karjalainen‐Lindsberg,et al.  Collagenase-1 (MMP-1), matrilysin-1 (MMP-7), and stromelysin-2 (MMP-10) are expressed by migrating enterocytes during intestinal wound healing , 2004, Scandinavian journal of gastroenterology.

[2]  J. Cook-Mills.  VCAM-1 signals during lymphocyte migration: role of reactive oxygen species. , 2002, Molecular immunology.

[3]  Y. Kohgo,et al.  The role of Paneth cells and their antimicrobial peptides in innate host defense. , 2004, Trends in microbiology.

[4]  Y. Naito,et al.  An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice , 2004, Inflammation Research.

[5]  J. Gordon,et al.  Bacterial Exposure Induces and Activates Matrilysin in Mucosal Epithelial Cells , 2000, The Journal of cell biology.

[6]  K. Ogawa,et al.  ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs , 2000, Inflammation Research.

[7]  R. Flisiak,et al.  Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity. , 2003, World journal of gastroenterology.

[8]  A. Ouellette,et al.  Activation of Paneth Cell α-Defensins in Mouse Small Intestine* , 2002, The Journal of Biological Chemistry.

[9]  C. J. Taylor,et al.  Matrix metalloproteinase levels are elevated in inflammatory bowel disease. , 1999, Gastroenterology.

[10]  J. Varani,et al.  The role of metalloelastase in immune complex-induced acute lung injury. , 2001, The American journal of pathology.

[11]  T. L. Deem,et al.  Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species. , 2004, Blood.

[12]  T. Wobbes,et al.  Plasma Levels of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-1 Correlate With Disease Stage and Survival in Colorectal Cancer Patients , 2005, Diseases of the colon and rectum.

[13]  T. Kirkegaard,et al.  Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn’s disease , 2004, Gut.

[14]  Parsons,et al.  The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease , 1999, Alimentary pharmacology & therapeutics.

[15]  C. Delacourt,et al.  Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. , 1996, American journal of respiratory cell and molecular biology.

[16]  F. Dunn,et al.  TIMP-1: A Marker of Left Ventricular Diastolic Dysfunction and Fibrosis in Hypertension , 2002, Hypertension.

[17]  F. Guarner,et al.  Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[18]  G. Dougan,et al.  Impaired Immunity to Intestinal Bacterial Infection in Stromelysin-1 (Matrix Metalloproteinase-3)-Deficient Mice1 , 2004, The Journal of Immunology.

[19]  W. Parks,et al.  Matrilysin in epithelial repair and defense. , 2001, Chest.

[20]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[21]  A. Torii,et al.  Vascular smooth muscle cells and pericytes express MMP‐1, MMP‐9, TIMP‐1 and type I procollagen in inflammatory bowel disease , 2001, Histopathology.

[22]  F. F. di Mola,et al.  Beneficial Effects of Batimastat (BB-94), a Matrix Metalloproteinase Inhibitor, in Rat Experimental Colitis , 2001, Digestion.

[23]  C. Joo,et al.  Wnt-7a Up-regulates Matrix Metalloproteinase-12 Expression and Promotes Cell Proliferation in Corneal Epithelial Cells during Wound Healing* , 2005, Journal of Biological Chemistry.

[24]  H. Nielsen,et al.  Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  A. Kang,et al.  The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis. , 1990, Arthritis and rheumatism.

[26]  F. Guarner,et al.  Therapeutic effect of phenantroline in two rat models of inflammatory bowel disease. , 2001, Scandinavian journal of gastroenterology.

[27]  F. Luscinskas,et al.  Neutrophils from MMP‐9‐ or neutrophil elastase‐deficient mice show no defect in transendothelial migration under flow in vitro , 2002, Journal of leukocyte biology.

[28]  L. Matrisian,et al.  Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. , 1999, Science.

[29]  J. Belaiche,et al.  Increased production of matrix metalloproteinase‐3 and tissue inhibitor of metalloproteinase‐1 by inflamed mucosa in inflammatory bowel disease , 2000, Clinical and experimental immunology.

[30]  C. J. Taylor,et al.  Expression of Matrix Metalloproteases in Inflammatory Bowel Disease , 1998, Annals of the New York Academy of Sciences.

[31]  T. Macdonald,et al.  Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease , 2000, Gut.

[32]  T. Macdonald,et al.  Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation , 2002, Gut.

[33]  T. Ohkusa,et al.  A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice , 1990 .

[34]  William C. Parks,et al.  Secretion of microbicidal α-defensins by intestinal Paneth cells in response to bacteria , 2000, Nature Immunology.

[35]  T. Betsuyaku,et al.  Neutrophil emigration in the lungs, peritoneum, and skin does not require gelatinase B. , 1999, American journal of respiratory cell and molecular biology.

[36]  A. Ashkenazi,et al.  A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. , 1998, Journal of immunology.

[37]  P. Khaw,et al.  Temporal and spatial expression of matrix metalloproteinases during wound healing of human corneal tissue. , 2003, Experimental eye research.

[38]  F. Guarner,et al.  Induction of Colonic Transmural Inflammation by Bacteroides Fragilis: Implication of Matrix Metalloproteinases , 2005, Inflammatory bowel diseases.

[39]  S. Weiss,et al.  Role of stromelysin 1 and gelatinase B in experimental acute lung injury. , 2001, American journal of respiratory cell and molecular biology.

[40]  H. Nielsen,et al.  Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. a validation study. , 2004, European journal of cancer.

[41]  P. Timms,et al.  Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1--possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis. , 2002, Hepato-gastroenterology.

[42]  C. López-Otín,et al.  Differential Expression of Three Matrix Metalloproteinases, MMP-19, MMP-26, and MMP-28, in Normal and Inflamed Intestine and Colon Cancer , 2004, Digestive Diseases and Sciences.